"ASPIRO Gene Therapy Trial In X-Linked Myotubular Myopathy (XLMTM): Update on Preliminary Safety And Efficacy Findings up to 72 Weeks Post-Treatment (1053)." Neurology
94.15 Supplement
(2020):
1053.
Web. 08 Feb. 2023.
Advertisement